Equity returns
On the base-case ramp, the network generates R275 million of EBITDA by Year 5. At hospital-group and healthcare exit multiples of 8×–12× EV/EBITDA, and after subtracting net debt, the equity value at a Year-5 exit implies attractive multiples on the total equity invested across both rounds (R830 million). Because the Series A and Series B are deployed at different times, the internal rate of return reflects that timing and the early J-curve. These returns are contingent on delivering the occupancy and rollout ramp and on the exit multiple achieved.
|
Measure |
8× exit |
10× exit |
12× exit |
|---|---|---|---|
|
Year-5 EBITDA (R m) |
275 |
275 |
275 |
|
Enterprise value (R m) |
2200 |
2750 |
3300 |
|
Less: net debt (R m) |
225 |
225 |
225 |
|
Equity value (R m) |
1975 |
2525 |
3075 |
|
MOIC on total equity (×) |
2.4× |
3.0× |
3.7× |
|
Blended equity IRR |
30.9% |
40.8% |
49.2% |
Key findingRead the returns with discipline
The returns are attractive and, unlike a small-base start-up, grounded in a substantial R275 million EBITDA base at a credible healthcare multiple. But they rest on three things: delivering the occupancy and rollout ramp, managing payer mix and tariffs, and achieving the exit multiple. The early J-curve losses and the significant capital deployed mean the multiple on invested capital is moderate (rather than the inflated figures a small-base model produces), which is the honest, realistic profile of a healthcare-infrastructure investment. Investors should underwrite the downside case below; realistic exits include a strategic acquisition by a hospital group, a development-finance or impact-investor transaction, or a listing.
Scenario analysis
|
Parameter |
Downside |
Base |
Upside |
|---|---|---|---|
|
Year-5 revenue (R m) |
858 |
1100 |
1210 |
|
Year-5 EBITDA (R m) |
209.0 |
275.0 |
297.0 |
|
Driver |
Slow occupancy / tariff pressure |
Sponsor plan |
Fast referral ramp; strong contracting |
|
Additional capital |
Likely required |
As planned |
In line / less |
Sensitivity
Equity returns are most sensitive to the exit multiple and to the occupancy and referral ramp, then to payer mix and tariffs, rollout pace, EBITDA margin and interest rates. The pattern reinforces the central message: value is created by filling the beds and centres through referral relationships and payer contracts, controlling clinical and staffing cost, proving outcomes, and building a national, evidence-based network that a strategic or development-finance buyer will pay a full multiple for, clinical and operational execution, not financial engineering.
Exit strategy and value realisation
HarmonyBridge is being built as an integrated, evidence-based, national paediatric healthcare network with several realisation routes. The most probable is a strategic acquisition by a major hospital group (such as Life Healthcare, Netcare, Mediclinic or Lenmed) seeking a differentiated paediatric transitional-care platform, a national footprint and diversified payer relationships. A development-finance or impact-investor transaction is a natural alternative given the social impact and the DFI-friendly infrastructure profile, and a listing is credible at the scale the network reaches. Because the network is strongly cash-generative once mature, continued operation with dividend distributions is a robust default. Value is maximised by proving occupancy, clinical outcomes and payer contracting, and by demonstrating a replicable, national model before a formal process.